Medical News

Analyzing the Existing Evidence of Mineralocorticoid Receptor Antagonist Treatment in HFpEF

The evidence-based treatment options for heart failure with preserved ejection fraction (HFpEF) are currently limited. The benefits of...

17 May, 2019

 
Email this page
Elevated Serum Nitric Oxide Metabolites Aggravate the CVD and Death Risk in Presence of Traditional Risk Factors

Elevated serum nitric oxide metabolites (NOx) levels above 30.5 and 32.5 μmol/L increase the risk of cardiovascular disease (CVD) mortality by 98%...

16 May, 2019

 
Email this page
Routine Calcium Channel Blocker Therapy Associated with better Clinical Outcomes following CABG with RA Graft

A recent study demonstrated that amongst coronary artery bypass grafting (CABG) patients with radial artery (RA) grafts, use of calcium channel...

13 May, 2019

 
Email this page
PURE Study: Education Level rather than Wealth Stronger Predictor of Major CVS Diseases Globally

The recently published “Prospective Urban Rural Epidemiologic” (PURE) study revealed that education rather than wealth was a more robust factor...

08 May, 2019

 
Email this page

Key Trials

VERDICT Trial: A Head-to-Head Comparison of Early vs. Standard Care Invasive Strategy in NTSE-ACS Patients

The VERDICT trial compared the long-term clinical outcomes following an early invasive coronary evaluation strategy vs. the standard invasive...

Six Months vs. Twelve Months of DAPT in Event-Free STEMI Patients after Primary PCI with Second Generation DES

The study demonstrated six months of DAPT to be non-superior to 12 months of DAPT in STEMI patients who remain event free after primary PCI with...

TRANSITION Study: Feasible and Safe to Initiate Sacubitril/Valsartan Pre-discharge in Acute HFrEF

The TRANSITION study indicates early initiation of sacubitril/valsartan pre-discharge in acute HFrEF patients is a feasible and safe option.

Impact of Sacubitril-Valsartan Treatment on Patients Hospitalized for Acute Decompensated HF

The PIONEER-HF trial ascertains the impact of sacubitril-valsartan therapy in hemodynamically stable patients hospitalized for acute decompensated...

Slide Library

Medical Management Strategy of CTEPH: Role of Riociguat

Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...

 
Email this page
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

 
Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

 
Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

 
Email this page

Our Publications

Gutron (Midodrine hydrochloride) Monograph

Orthostatic Hypotension is common in elderly (>70 years of age) and can also occur secondary to neuropathy like in diabetes or central lesions...

Azmarda (Sacubitril/Valsartan) FAQs

This booklet on frequently asked questions on sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) provides...

Retefast (Reteplase) Datasheet

This datasheet provides an overview on the pharmacology, clinical efficacy, safety, indications and dosage of reteplase.

The Changing Landscape of CV Risk Reduction - Is LDL Lowering Sufficient: Questions & Answers (Dr. Michael Miller, USA)

Here is a set of questions addressed by Dr. Michael Miller, a renowned cardiologist and lipidologist during the “PROMISE” meet held in India.

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 

Hypertension

Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 

Poll

What percent of your patients who need oral anticoagulation, receive warfarin?
<20%
28% (5 votes)
20-40%
17% (3 votes)
40-50%
11% (2 votes)
50-70%
11% (2 votes)
70-80%
28% (5 votes)
Almost all
6% (1 vote)
Total votes: 18